Obesity Injections May Have Fewer Weight Loss Effects In Real World: Study
Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found.
Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide (Zepbound and Mounjaro) are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar.
The study, published in the Obesity Journal, examined the effects of anti-obesity injectables on weight reduction and blood sugar regulation (glycaemic control) in a real-world setting.
"Our study shows that patients treated for obesity with semaglutide or tirzepatide lost less weight on average in a regular clinical setting compared to what is observed in randomised clinical trials," lead author Dr Hamlet Gasoyan, a researcher with the Cleveland Clinic, US, said.
"According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomised clinical trial settings," Dr Gasoyan said.
The researchers examined 7,881 adult patients with an average body mass index (BMI) of over 39 -- classified as 'severe obesity'. Of these, 1,320 had pre-diabetes at the start of the study, which meant they were at a higher risk of developing type 2 diabetes.
The participants were started on obesity treatments between 2021 and 2023 with semaglutide or tirzepatide injectables.
Following up on the participants a year after starting with the treatment, the average weight loss among those who discontinued injections within three months was 3.6 per cent, compared to 6.8 per cent in those who discontinued within 3-12 months.
"Mean percentage weight reduction at one year was 8.7 per cent, and it was 3.6 per cent with early discontinuation (three months), 6.8 per cent with late discontinuation (3-12 months) and 11.9 per cent with no discontinuation," the authors wrote.
Furthermore, those on a high-maintenance dosage -- the amount required to sustain the effects of the medication -- lost 13.7 per cent of their body weight with semaglutide and 18 per cent with tirzepatide, the researchers said.
Among the participants having pre-diabetes, 33 per cent of those who stopped taking injections within three months experienced normal blood sugar levels, compared to 41 per cent who discontinued within 3-12 months, and 67.9 per cent of those who did not discontinue treatment.
"The average weight reduction in this cohort was lower than that observed in the main phase 3 (clinical) trials, likely because of higher rates of discontinuation and lower maintenance dosages," the team wrote.
They identified that those not discontinuing medications or taking a high-maintenance dose were among the factors related to more chances of losing at least 10 per cent of one's body weight in a year.
Overall, over a fifth of the study group was found to have discontinued their medications within three months of the study's start, while 32 per cent discontinued within 3-12 months.
Reasons for discontinuing treatment included costs and insurance-related issues, side effects and medication shortages, the researchers said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
First Post
8 hours ago
- First Post
The Burden of Weight Loss Drugs: Is It Worth the Risk? Vantage with Palki Sharma
The Burden of Weight Loss Drugs: Is It Worth the Risk? | Vantage with Palki Sharma | N18G Weight loss drugs like Ozempic, Wegovy, and Mounjaro are being hailed as revolutionary, reshaping bodies, lives, and a booming $15 billion industry. But behind the hype lies a growing concern: shortages, black markets, and serious side effects ranging from stomach paralysis to suicidal thoughts. As demand soars and influencers drive the trend, experts warn we may be living through a massive human experiment. See More
Hindustan Times
a day ago
- Hindustan Times
Better than Ozempic? Nutritionist shares 3 powerful drinks that burn belly fat naturally
Looking for a natural alternative to fat-loss injections like Ozempic? Nutritionist Sakshi Lalwani shares in her June 6 Instagram post 3 simple yet powerful drinks that can help accelerate fat burn, boost your metabolism, and support long-term weight management, without the side effects. Discover 3 simple drinks for effective fat burn and metabolism support. (Pixabay) 1. Moringa and mint detox water: The hormonal fat burner Recipe: Add 1 tsp moringa powder and a few crushed mint leaves to 1 glass of warm water. Let it steep for 5 minutes. Why it works: Balances blood sugar levels Reduces cortisol (the belly fat hormone) Supports liver detox (crucial for burning stubborn fat) Best time to drink: Mid-morning or between meals Bonus: Boosts iron levels and energy during weight loss 2. Black jeera water: The deep belly fat mobiliser Recipe: Boil ½ tsp kala jeera (black cumin) in 1.5 cups of water for 5 minutes. Strain and sip warm. Why it works: Boosts thermogenesis (burns fat through heat production) Activates brown fat (which helps burn stored white fat) Improves thyroid function Best time to drink: On an empty stomach in the morning Bonus: Supports metabolism naturally with no side effects 3. Bael leaf and ginger infusion: The belly bloat blaster Recipe: Boil 4–5 bael leaves and ½ inch grated ginger in 2 cups of water. Reduce to 1 cup, strain, and sip. Why it works: Repair the gut lining for efficient fat digestion Regulates insulin levels Reduces bloating—ideal for those with PCOS or IBS Best time to drink: After lunch or in the evening Bonus: Aids digestion and enhances liver function Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
Indian Express
a day ago
- Indian Express
Eli Lilly's weight loss drug most effective at preventing heart attacks and strokes: What new study means for Mounjaro users
US pharmaceutical giant Eli Lilly's weight-loss drug tirzepatide was found to be more effective in preventing heart attacks and strokes compared to its previous GLP-1 medication dulaglutide. The preliminary results from a yet-to-be published large trial showed that the risk of a major adverse cardiovascular event was eight per cent lower in people who were put on the new therapy. Tirzepatide is sold under the brand name Mounjaro. Belonging to a group of medicines called incretin mimetics — which mimic hormones that play a key role in regulating insulin levels, blood sugar levels and appetite — both the medicines were initially approved for the treatment of diabetes, with tirzepatide later receiving approval for the treatment of obesity and other related conditions such as obstructive sleep apnea. Dulaglutide mimics the action of the GLP1 hormone while tirzepatide mimics the combined action of GLP1 and GIP hormones. The trial found an eight per cent lower risk of major adverse cardiovascular events such as cardiovascular deaths, heart attacks and strokes in people who were on tirzepatide as compared to those on dulaglutide. Tirzepatide was found to reduce the risk of such events by 28 per cent against a placebo, by comparing the results of the current trial with a 2019 trial of dulaglutide against placebo. Another important finding of the trial was a 16 per cent lower risk of all-cause mortality in people who were on tirzepatide, compared to those on dulaglutide. The company said that the medicine reduced the risk of all-cause mortality by 39 per cent against placebo — again by comparing data from the current trial with the 2019 dulaglutide trial. The current trial also demonstrated that tirzepatide was better at slowing the decline of kidney function in participants who were at a high risk of chronic kidney disease. Tirzepatide slowed the decline in the kidney's filtration rate by 3.54 mL/min/1.73 m2 as compared to dulaglutide. The trial also showed that tirzepatide was more effective at reducing three-month average blood glucose levels as well as weight when compared to dulaglutide. The use of tirzepatide led to a 1.73 per cent reduction in HbA1c levels at 36 months as compared to 0.9 per cent with dulaglutide use. The participants on tirzepatide dropped 12 per cent of their body weight during the trial period as compared to 4.95 per cent with dulaglutide. With the new generation weight-loss drugs gaining popularity across the globe, it is essential for these drugs to demonstrate protection against heart diseases, especially since it is a common comorbidity along with obesity and diabetes. While there is a link between uncontrolled blood glucose levels and heart disease, not all diabetes medicines protect the heart. In fact, a previous class of diabetes medicines called glitazones were found to increase the risk of heart failure. With the end-game of these medicines being saving lives — and not just controlling blood glucose levels or body weight — the US Food and Drug Administration now requires the medicines to demonstrate that they do not harm the heart or, better yet, they offer protection against cardiovascular events. The new classes of diabetes medicines such as GLP-1 and SGLT-2 were found to protect the heart as well. Importantly, the competitor of Eli Lilly's tirzepatide — Novo Nordisk's semaglutide — has FDA approval as treatment for reducing risk of heart diseases. These medicines work by improving the secretion of insulin, which helps in removing glucose from the blood to the cells for use as energy. They inhibit the secretion of the hormone glucagon that stimulates the liver to release stored glucose into the bloodstream, slow down the emptying of the stomach so that the blood glucose levels do not spike suddenly and reduce appetite by signalling to the brain that you are full. The drugs have become popular owing to their weight-loss properties, which at times can be as effective as bariatric surgery. Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
